Akoya Biosciences Inc. said an in-depth comparison of immuno-oncology biomarker types determined that multiplex immunofluorescence with spatial characterization significantly outperformed other biomarker testing approaches for predicting patient response to treatments targeting PD-1/PD-L1.
More than a year after a catastrophic shortage of platinum-based chemotherapy drugs swept through the U.S., FDA on June 28 officially removed carboplatin and cisplatin from the drug shortage list.
